Economic aspects of treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

A review of the literature dedicated to the economic aspects of drug and surgical treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) is presented in the article. Currently, symptomatic therapy, which usually leads to an increase in the financial costs associated with the complications and surgical treatment, is most commonly used. The pathogenetic treatment of BPH (5-alpha reductase inhibitors), including combination therapy, requires an increase in costs, but it is also considered the most cost-effective approach. Despite the continuous growing of therapeutic armamentarium, the surgical treatment is still relevant and holds an important place. A lot of studies have shown that open procedures are inferior to endoscopic and minimally invasive interventions by both clinical and cost-effective results. At the same time, transurethral interventions on the prostate does not exclude economic losses due to the necessity of expensive laser technologies and the development of complications in the early postoperative period. Thus, currently, the best treatment option should be chosen not only on individual basis, but also depending on economic aspects based on a balanced medical and economic analysis of each treatment method.

全文:

受限制的访问

作者简介

V. Startsev

GBOU VO «Saint-Petersburg State Pediatric Medical University»; FGBNU “Institute of Experimental Medicine” of Russian Academy of Science

Email: doc.urolog@gmail.com
MD, associate professor, professor at the Department of Oncology, Pediatric Oncology and Radiation Therapy, Head of the Surgical Department Saint-Petersburg, Russia

V. Dudarev

FGbOu VO «Chita State Medical University»

Email: dudarevv94@gmail.com
assistant at the Department of Faculty Surgery with the course of Urology Chita, Russia

F. Sevryukov

Privolzhsky Research Medical University of the Ministry of Health of the Russia; 'Clinical Hospital at Nizhny Novgorod Railway Station of JSC «RZD»

Email: fedorsevrukov@mail.ru
MD, associate professor, professor at the Department of Urology named after E.V. Shakhov, Head of the Department of Urology Nizhny Novgorod, Russia

N. Zabrodina

FGBOU DPO RMANPO; Central Clinical Hospital of civil aviation

Email: nbzabrodina@gmail.com
MD, professor at the Department of endoscopic urology, Chief of Central Clinical Hospital of civil aviation Moscow, Russia

参考

  1. Gravas S., Bachmann A, Descazeaud A, Drake M. et al. EAU guidelines on the management of non-neurogenic male lower urinary tract symptoms, incl. benign prostatic obstruction. Eur Urol. 2017:5.
  2. Hayashi K, Fukagai T, Koshikiya A, Igarashi A. et al. Effect of tadalafil that was additionally administered to patients receiving an alfal-blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Nihon Hinyokika Gakkai Zasshi. 2016.107(1).28-33.
  3. Homma Y, Gotoh M, Yokoyama O, Masumori N. et. al. Outline of JUA clinical guidelines for benign prostatic hyperplasia. Int J Urol. 2011;18(11).741-756.
  4. Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary care setting. Can J Urol. 2012.19(suppl 1).10-17.
  5. Земскова С.С., Шабунина В.И., Гертнер Л.В., Мухин В.Б. и соавт. Влияние консервативного и оперативного лечения заболеваний мочеполовых органов на иммунологическую реактивность пациентов. Вестник экспериментальной и клинической хирургии. 2010;3(4):408-414).
  6. Parsons J.K. Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr. Bladder Dysfunct. Rep. 2010;5(4):212-218.
  7. Logic J.W. Lower urinary tract symptoms suggestive of benign prostatic obstruction: Triumph - the role of general practice data-bases. J.W. Logic, G.M. Clifford, R.D.T. Farmer. Eur. Urol. 2001(Suppl. 3):42-47.
  8. Аполихин О.И., Сивков А.В., Золотухин О.В., Шадеркин И.А и соавт. Распространенность симптомов нарушения функции нижних мочевых путей у мужчин по результатам популяционного исследования. Экспериментальная и клиническая урология. 2018. № 1. С 4-12).
  9. Просянников М.Ю. Медикоэкономическая эффективность стандартизированной программы диагностики и лечения доброкачественной гиперплазии предстательной железы. Автореферат дисс. канд. мед. наук: 14.02.03. М., 2014. 25 с.).
  10. Коротеев М.А., Кореньков Д.Г., Михайличенко В.В. Ранняя профилактика инфекционно-воспалительных осложнений трансуретральной резекции доброкачественной гиперплазии предстательной железы. Андрология и генитальная хирургия. 2008. № 2. С. 55-61.
  11. Oelke M, Bachmann A, Descazeaud A, Emberton M. etal. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013. № 64(1). P. 118-140.
  12. Аляев Ю.Г., Рапопорт Л.М., Винаров А.З., Цариченко Д.Г. и соавт. Особенности предоперационной подготовки и лечения при гиперплазии простаты больших размеров. Андрология и генитальная хирургия. 2009;1:50-53.
  13. Kaplan A.L., Agarwa N, Setlur N.P., Tan H.J. et al. Measuring the cost of care in benign prostatic hyperplasia using time-driven activity-based costing (TDABC). Healthc (Amst). 2015;3(1):43-48.
  14. Lee S.W., Chan E.M., Lai Y.K. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. Sci Rep. 2017;7(1):7984. doi: 10.1038/s41598-017-06628-8.
  15. Wei J.T., Calhoun E, Jacobsen S.J. Urologic diseases in america project: benign prostatic hyperplasia. J Urol. 2008; 179(5 Suppl):S. 75-80.
  16. Izard J., Nickel J.C. Impact of medical therapy on transurethral resection of the prostate: two decades of change. BJU Int. 2011 ;108( 1):89-93. doi: 10.1111/j.1464-410X.2010.09737. x.
  17. Filson C.P., Wei J.T., Hollingsworth J.M. Trends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2013;82:1386-1392. doi: 10.1016/j.urology.2013.07.062.
  18. Cindolo L, Pirozzi L, Fanizza C. et al. Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men. Int Urol Nephrol. 2014;46:695-701. doi: 10.1007/s11255-013-0587-8.
  19. Bishr M, Boehm K, Trudeau V., Tian Z. et al. Medical management of benign prostatic hyperplasia: Results from a population-based study. Can UrolAssoc J. 2016;10(1-2): 55-59.
  20. Gravas S., Bachmann A, Descazeaud A, Drake M. et al. EAU guidelines on the management of non-neurogenic male lower urinary tract symptoms, incl. benign prostatic obstruction. Eur Urol. 2014:29-32.
  21. Nickel J.C, Downey J., Benard F, Chetner M. et al. The Canadian Benign Prostatic Hyperplasia Audit Study (CanBas). Can Urol Assoc J 2008;2(4):367-373. Levi A., Deter L.A. [Chief Editor: Edward David Kim E.D,] Benign Prostatic Hyperplasia (BPH) Treatment & Management Updated: Dec 18, 2017. URL https://emedicine.medscape.com/article/437359-treatment
  22. Шпиленя Е.С., Шадеркина В.А. Экономические аспекты лечения доброкачественной гиперплазии предстательной железы. Экспериментальная и клиническая урология 2018;2:84-89.
  23. Пушкарь Д.Ю., Раснер П.И., Абоян И.А., Асфандияров Ф.Р. и соавт. «СНМП/ДГПЖ - Кто лечит?». Результаты эпидемиологического исследования. Урология 2019;1:5-15.
  24. Foo K.T. What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? World J Urol. 2019 Feb 25. doi: 10.1007/s00345-019-02691-0.
  25. Симченко Н.И., Лемтюгов М.Б., Быкова О.О. Альтернативный подход в терапии острой задержки мочи при доброкачественной гиперплазии предстательной железы. Проблемы здоровья и экологии. 2017;1(51):54-57).
  26. Geitona M, Karabela P, Katsoulis I.A., Kousoulakou H. et al. Dutasteride plus tamsulosin fixed-dose combination first-line therapy versus tamsulosin monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting. BMC Urol. 2014;14:78. doi: 10.1186/1471-2490-14-78.
  27. Wu D.B., Yee C.H., Ng C.F., Lee S.W. et al. Economic Evaluation of Combination Therapy Versus Monotherapy for Treatment of Benign Prostatic Hyperplasia in Hong Kong. Front Pharmacol. 2018;9:1078. Doi: 10.3389/ fphar.2018.01078.
  28. Morlock R, Goodwin B, Gomez R.G., Eaddy M. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5a-reductase inhibitor therapy and a-blocker therapy: a retrospective analysis. Clin Ther. 2013;35:624-33.
  29. Gill B.C., Ulchaker J.C. Costs of managing benign prostatic hyperplasia in the office and operating room. Curr Urol Rep. 2018;19(9):72. Doi: 10.1007/ s11934-018-0822-z.
  30. Messina R, Mirone V. Benign prostatic hyperplasia an economic assessment of fixed combination therapy based on a literature review. Arch Ital di Urol Androlorgano Uff [di] Soc Ital di Ecogr Urol e Nefrol. 2015;87:185-189.
  31. Nazir J., Heemstra L., van Engen A., Hakimi Z., Ivanescu C. Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia. BMC Urol. 2015;15:41. Doi: 10.1186/ s12894-015-0031-8.
  32. Order of the Government of the Russian Federation of December 10, 2018 No. 2738-p. (Распоряжение правительства РФ от 10.12. 2018. № 2738-р. https:// www.garant.ru/products/ipo/prime/doc/72023048 [Дата обращения -20.06.2019])
  33. Meshkovskij A.P. On the problems of drug provision of the population. Medicinskie tehnologii. Ocenka i vybor. 2015;3:21-34. (Мешковский А.П. О проблемах лекарственного обеспечения населения. Медицинские технологии. Оценка и выбор. 2015 № 3. C. 21-34).
  34. Gallo C.B., Miranda A.F., Felix-Patricio B., Ramos C.F. et al. Effects of castration and hormone replacement in the urinary bladder of rats: structural, ultrastructural, and biochemical analysis. J Androl. 2012;33:684-690. doi: 10.2164/jandrol.111.014159.
  35. Gacci M., Corona G., Sebastianelli A., Serni S., DeNunzio C., Maggi M., et al. Male lower urinary tract symptoms and cardiovascular events: a systematic review and meta-analysis. Eur Urol. 2016;70:788-796. Doi: 10.1016/j. eururo.2016.07.007.46.
  36. Haider K.S., Haider A, Doros G, Traish A. Long-term testosterone therapy improves urinary and sexual function, and quality of life in men with hypogonadism: results from a propensity matched subgroup of a controlled registry study. J Urol. 2018;199:257-265. doi: 10.1016/j.juro.2017.07.039.
  37. Kim B.S., Ko Y.H., Song P.H., Kim T.H. et al. Prostatic urethral length as a predictive factor for surgical treatment of benign prostatic hyperplasia: a prospective, multiinstitutional study. Prostate Int. 2019;7(1):30-34. doi: 10.1016/j.prnil.2018.06.002.
  38. Mathieu R, Lebdai S, Cornu J.N., Benchikh A. et al. Perioperative and economic analysis of surgical treatments for benign prostatic hyperplasia: A study of the French committee on LUT. Progresen Urologie 2017, 27(6):362-368.
  39. Patel R.M., Bariol S. National trends in surgical therapy for benign prostatic hyperplasia in Australia. ANZ J Surg. 2019;89(4): 345-349. Doi: 10.1111/ ans.15016.
  40. Treharne C, Crowe L, Booth D, Ihara Z. Economic Value of the Transurethral Resection in Saline System for Treatment of Benign Prostatic Hyperplasia in England and Wales: Systematic Review, Meta-analysis, and Cost-Consequence Model. Eur Urol Focus. 2018;4(2):270-279. doi: 10.1016/j.euf.2016.03.002.
  41. Descazeaud A., Robert, G, Lebdai S. et al. Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. World J Urol. 2011;29:211-216.
  42. Reich O, Gratzke C, Bachmann A. et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180:246-249.
  43. Rassweiler J, Teber, D, Kuntz, R, Hofmann, R. Complications of transurethral resection of the prostate (TURP) - incidence, management, and prevention. Eur Urol. 2006;50:969-979.
  44. Hawary A., Mukhtar K, Sinclair A., Pearce I. Transurethral resection of the prostate syndrome: almost gone but not forgotten. J Endourol. 2009; 23: 2013-2020.
  45. Marszalek M, Ponholzer A, Pusman M, Berger I., Madersbacher S. Transurethral resection of the prostate. Eur Urol Suppl. 2009;8:504-512.
  46. O’Donnell A.M., Foo I.T.H. Anaesthesia for transurethral resection of the prostate. Continuing Educ Anaesth Crit Care Pain. 2009;9:92-96.
  47. Treharne C, Crowe L, Booth D, Ihara Z. Economic Value of the Transurethral Resection in Saline System for Treatment of Benign Prostatic Hyperplasia in England and Wales: Systematic Review, Meta-analysis, and Cost-Consequence Model. Eur Urol Focus. 2018;4(2):270-279. doi: 10.1016/j.euf.2016.03.002.
  48. Kirby R.S., Kirby M, Fitzpatrick J.M. Benign prostatic hyperplasia: counting the cost of its management. BJU Int 2010;105(7):901-902.
  49. Jeon B.J., Chung H, Bae J.H., Jung H. et al. Analysis of Present Status for Surgery of Benign Prostatic Hyperplasia in Korea Using Nationwide Healthcare System Data. Int Neurourol J. 2019;23(1):22-29.
  50. Gilling P, Barber N, Bidair M, Anderson P. et al. Water: a double-blind, randomized, controlled trial of aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. J Urol. 2018;199(5):1252-1261. doi: 10.1016/j.juro.2017.12.065.
  51. Takahashi N., Watanabe N., Nakamura K., Tsukamoto T. et al. The 10-year outcomes of PVP (photoselective vaporization of the prostate) for treating BPH (benign prostatic hyperplasia). Nihon Hinyokika Gakkai Zasshi. 2018;109(2):85-89. doi: 10.5980/jpnjurol.109.85.
  52. Rai P., Srivastava A., Dhayal I.R., Singh S. Comparison of safety, efficacy and cost effectiveness of photoselective vaporization with bipolar vaporization of prostate in benign prostatic hyperplasia. Curr Urol. 2017;11:103-109.
  53. Hsu Y.C., Lin Y.H., Chou C.Y., Hou C.P. et al. Economic evaluation study (cheer compliant) laser prostatectomy for benign prostatic hyperplasia: Outcomes and cost-effectiveness. Med (United States). 2016;95:1-5.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2019